Combination strategies are rapidly redefining treatment for HER2-positive solid tumors. | HER2 combination strategies are evolving. Hear how biology and next-generation antibodies are redefining treatment.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Early-onset cancers are rising among adults 18–49, reshaping how patients are diagnosed, supported, and engaged. This report…
In the past two weeks, CARsgen Therapeutics won the world's first regulatory approval for a solid tumor CAR-T, a…
Antibody-drug conjugates from Kelun-Biotech and Hansoh Pharma, respectively partnered with Merck & Co. and GSK, delivered…
While dealmaking and investment dollars may be flowing across biopharma once again, acute challenges tied to policy, pricing and…
By Moitreyee Chatterjee-Kishore, Ph.D., MBA, Head of Oncology Development, Astellas Pharma Inc. | How targeted protein degraders…
The FDA has approved a new | The FDA has approved a new small molecule inhibitor from Celcuity with blockbuster potential that…
